Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy

Human Gene Therapy

Volumn 24, Issue 2, 2013, Pages 209-219

  Mussche, Silke ^a   Devreese, Bart ^b   Nagabhushan Kalburgi, Sahana ^c   Bachaboina, Lavanya ^c   Fox, Jonathan C ^c   Shih, Hung Jui ^c   Van Coster, Rudy ^a   Samulski, R Jude ^c   Gray, Steven J ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GIGAXONIN; PARVOVIRUS VECTOR; PROTEOME; UNCLASSIFIED DRUG; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOSKELETON; GAN GENE; GENE; GENE TRANSFER; GIANT AXONAL NEUROPATHY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; SKIN FIBROBLAST;

ANIMALS; CELLS, CULTURED; CYTOSKELETAL PROTEINS; CYTOSKELETON; DEPENDOVIRUS; FIBROBLASTS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GIANT AXONAL NEUROPATHY; HEK293 CELLS; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; PRIMARY CELL CULTURE; PROTEOME; RNA, MESSENGER; TRANSFECTION; VIMENTIN;

EID: 84874310194     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.107     Document Type: Article

References (37)

1. Allen, E., Ding, J., Wang, W., et al. (2005). Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. Nature 438, 224-228.
2. Berg, B.O., Rosenberg, S.H., and Asbury, A.K. (1972). Giant axonal neuropathy. Pediatrics 49, 894-899.
3. Bomont, P., and Koenig, M. (2003). Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization. Hum. Mol. Genet. 12, 813-822.
4. Bomont, P., Cavalier, L., Blondeau, F., et al. (2000). The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat. Genet. 26, 370-374.
5. Bomont, P., Ioos, C., Yalcinkaya, C., et al. (2003). Identification of seven novel mutations in the GAN gene. Hum. Mutat. 21, 446.
6. Bruno, C., Bertini, E., Federico, A., et al. (2004). Clinical and molecular findings in patients with giant axonal neuropathy (GAN). Neurology 62, 13-16.
7. Cleveland, D.W., Yamanaka, K., and Bomont, P. (2009). Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway. Hum. Mol. Genet. 18, 1384-1394.
8. D'Andrea, A., and Pellman, D. (1998). Deubiquitinating enzymes: a new class of biological regulators. Crit Rev. Biochem. Mol. Biol. 33, 337-352.
9. Demir, E., Bomont, P., Erdem S, et al. (2005). Giant axonal neuropathy: clinical and genetic study in six cases. J. Neurol. Neurosurg. Psychiatry 76, 825-832.
10. Dequen, F., Bomont, P., Gowing, G., et al. (2008). Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1. J Neurochem. 107, 253-264.
11. Ding, J., Liu, J.J., Kowal, A.S., et al. (2002). Microtubuleassociated protein 1B: a neuronal binding partner for gigaxonin. J. Cell Biol. 158, 427-433.
12. Ding, J., Allen, E., Wang, W., et al. (2006). Gene targeting of GAN in mouse causes a toxic accumulation of microtubuleassociated protein 8 and impaired retrograde axonal transport. Hum. Mol. Genet. 15, 1451-1463.
13. Duque, S., Joussemet, B., Riviere, C., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196.
14. Federici, T., Taub, J.S., Baum, G.R., et al. (2012). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 19, 852-859.
15. Furukawa, M., He, Y.J., Borchers, C., Xiong, Y. (2003). Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat. Cell Biol. 5, 1001-1007.
16. Ganay, T., Boizot, A., Burrer, R., et al. (2011). Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice. Mol. Neurodegener. 6, 25.
17. Gerard, M., Deleersnijder, A., Daniëls, V., et al. (2010). Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J. Neurosci. 30, 2454-2463.
18. Gray, S.J., Blake, B.L., Criswell, H.E., et al. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570-578.
19. Gray, S.J., Choi, V.W., Asokan, A., et al. (2011a). Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr. Protoc. Neurosci. Chapter 4: Unit 4.17.
20. Gray, S.J., Matagne, V., Bachaboina, L., et al. (2011b). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069.
21. Gray, S.J., Nagabhushan Kalburgi, S., McCown, T.J., and Jude Samulski, R. (2013). AAV9 transduction in the central nervous system of non-human primates. Hum. Gene Ther. doi: 10.1038/gt.2012.101.
22. Houlden, H., Groves, M., Miedzybrodzka, Z., et al. (2007). New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy. J. Neurol. Neurosurg. Psychiatry 78, 1267-1270.
23. Koop, O., Schirmacher, A., Nelis, E., et al. (2007). Genotypephenotype analysis in patients with giant axonal neuropathy (GAN). Neuromuscul. Disord. 17, 624-630.
24. Kuhlenbäumer, G., Young, P., Oberwittler, C., et al. (2002). Giant axonal neuropathy (GAN): case report and two novel mutations in the gigaxonin gene. Neurology 58, 1273-1276.
25. Leung, C.L., Pang, Y., Shu, C., et al. (2007). Alterations in lipid metabolism gene expression and abnormal lipid accumulation in fibroblast explants from giant axonal neuropathy patients. BMC Genet. 8, 6.
26. McCarty, D.M., Fu, H., Monahan, P.E., et al. (2003). Adenoassociated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112-2118.
27. Mussche, S., De Paepe, B., Smet, J., et al. (2012). Proteomic analysis in giant axonal neuropathy: New insights into disease mechanisms. Muscle Nerve doi: 10.1002/mus.23306.
28. Nalini, A., Gayathri, N., Yasha, T.C., et al. (2008). Clinical, pathological and molecular findings in two siblings with giant axonal neuropathy (GAN): report from India. Eur. J. Med. Genet. 51, 426-435.
29. Pena, S.D., Opas, M., Turksen, K., et al. (1983). Immunocytochemical studies of intermediate filament aggregates and their relationship to microtubules in cultured skin fibroblasts from patients with giant axonal neuropathy. Eur. J. Cell Biol. 31, 227-234.
30. Perkins, D.N., Pappin, D.J., Creasy, D.M., and Cottrell, J.S. (1999). Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567.
31. Prineas, J.W., Ouvrier, R.A., Wright, R.G., et al. (1976). Giant axonal neuropathy-generalized disorder of cytoplasmic microfilament formation. J. Neuropathol. Exp. Neurol. 35, 458-470.
32. Reidegeld, K.A., Eisenacher, M., Kohl, M., et al. (2008). An easyto-use Decoy Database Builder software tool, implementing different decoy strategies for false discovery rate calculation in automated MS/MS protein identifications. Proteomics 8, 1129-1137.
33. Snel, B., Lehmann, G., Bork, P., and Huynen, M.A. (2000). STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 2000. 28, 3442-3444.
34. Sowa, M.E., Bennett, E.J., Gygi, S.P., and Harper, J.W. (2009). Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403.
35. Wang, W., Ding, J., Allen, E., et al. (2005). Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway. Curr. Biol. 15, 2050-2055.
36. Wilkinson, K.D. (2000). Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell Develop. Biol. 11, 141-148.
37. Zhang, D.D., Lo, S.C., Sun, Z., et al. (2005). Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 280, 30091-30099.